|Awarded On||August 24, 2018|
|Title||Small Molecule for Selective Targeting of Epithelial-Mesenchymal Transition-Induced Cancer Stem Cells|
|Award Mechanism||High Impact/High Risk|
|Principal Investigator/Program Director||Joe Taube|
Nearly half of triple-negative breast cancer (TNBC) patients fail to respond to chemotherapy and suffer median survival rates fewer than 3 years. While hormone- and growth factor receptor-targeted drug treatments have improved outcomes for other subtypes of breast cancer, patients with TNBC face limited options and eventually succumb to either primary tumor recurrence or distant metastases. For TNBC patients with brain metastases median overall survival is less than 5 months. Tumors are composed of a mixture of distinct cell sub-types which unequally drive progression and response to treatment. Cancer stem cells (CSCs) are often present as a subpopulation of most breast cancers and are resp...